“I always start by saying I have a day job and a gay job,” opened OUTbio founder Ramsey Johnson. By day, Johnson works as vice president of clinical operations of Aditum Bio. In his spare time, he runs the non-profit OUTbio, a growing LGBTQ professionals group for the biotech industry.
A Day Job And A Gay Job: How OUTbio Is Connecting LGBTQ Biotech Executives
Networking Organization Now Has Branches Across The US, UK And Ireland
LGBTQ networking group OUTbio has gone from strength to strength since it was founded in 2015, from a small event attended by a handful of executives in Boston to a registered non-profit with affiliated groups across the US alongside international branches.
More from Leadership
• By
Laura Lane, European head of Lilly Ventures, talked to In Vivo at the recent Bio-Europe meeting in a fireside chat about how strategic investments are shaping the future of biotech, Lilly's approach to early-stage innovation, and the evolving European investment landscape.
• By
Regenxbio is riding a wave these days, with all three of its clinical-stage programs set to reach critical milestones this year and recent positive news on its DMD gene therapy, just as Sarepta suffered a setback with a death related to its DMD treatment. In Vivo spoke with CEO Curran Simpson about the company’s plans and strategic decisions.
• By
From a $7m discarded asset to a $336m commercial portfolio, In Vivo looks inside Mirum Pharma’s disciplined strategy for identifying, acquiring and revitalizing overlooked rare disease programs while building toward billion-dollar potential.
• By
A perspective on global healthcare trends and UK opportunities from Yogan Patel, head of life sciences at chartered accountancy MHA, a member firm of Baker Tilley International.
More from In Vivo
• By
TechBio stands at a critical inflection point, where computational innovation meets the reality of biopharma. Industry leaders have begun to cut through the hype and identify where sustainable value truly lies in this rapidly evolving landscape.
• By
Three $1bn+ alliances were penned in February, and one exceeded $2bn.
• By
From a $7m discarded asset to a $336m commercial portfolio, In Vivo looks inside Mirum Pharma’s disciplined strategy for identifying, acquiring and revitalizing overlooked rare disease programs while building toward billion-dollar potential.